EUVIMEDEUVIMED entdecken
Open Access

GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD

Irving Levine iD, Shaina Sekhri, William Schreiber-Stainthorp iD, Brandon Locke, Olivia Delau, Mohamed Elhawary, Krutika Pandit, Xucong Meng, Jordan Axelrad iD

Inflammatory Bowel Diseases · 10.02.2025 · 31 (2) · 467-475

DOI: 10.1093/ibd/izae250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 22.10.2024. Verfasst von Irving Levine und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, NYU Langone Health, Manhattan, NY 10016, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Inflammatory Bowel Diseases, Hypoglycemic Agents. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Crohn's and Colitis Foundation, Judith Stewart Colton Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In patients with inflammatory bowel disease (IBD), multimorbidity with obesity and type 2 diabetes is common and increasing. Glucagon-like peptide 1 (GLP-1) receptor agonists are increasingly being prescribed for patients with IBD, yet their impact on patients with IBD is largely unknown. We aimed to assess the impact of GLP-1 receptor agonists on the course of IBD.

Methods

We identified all IBD patients prescribed GLP-1 receptor agonists at a large academic healthcare network between 2009 and 2023. We analyzed demographics and IBD characteristics in the year pre- and post–GLP-1 receptor agonist prescription and matched them to non-IBD controls. Our primary outcome was IBD exacerbation in the year following GLP-1 receptor agonist initiation, measured as a composite of IBD-related hospitalization, corticosteroid prescription, medication escalation or changes, or IBD-related surgery. Secondary outcomes included change in metabolic risk factors.

Results

Overall, 224 patients met inclusion criteria. At GLP-1 receptor agonist initiation, the median age was 54 years, 63% were female, 77% were White, and median BMI was 33.2 kg/m2. Compared to the 12-month period prior to GLP-1 receptor agonist initiation, in the 12 months post–GLP-1 receptor agonist initiation, there was no change in rates of IBD exacerbation, IBD-related hospitalization, steroids prescription, medication escalation or changes, or IBD-related surgery. There was a significant decrease in BMI in the year following GLP-1 receptor agonist initiation (median BMI 33.5 vs 31.6 kg/m2, P < .01), with rates of decrease comparable to non-IBD matched controls.

Conclusions

In patients with IBD, GLP-1 receptor agonists are effective for weight loss and associated with few episodes of disease exacerbation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsInflammatory Bowel DiseasesHypoglycemic AgentsHumansFemaleMaleMiddle AgedAdultHospitalizationDisease ProgressionRetrospective StudiesAgedCase-Control StudiesDiabetes Mellitus, Type 2

Stichwörter der Autor:innen

GLP-1 receptor agonistsIBDhealthcare maintenanceobesity

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, NYU Langone Health, Manhattan, NY 10016, USA.
  • Department of Medicine, NYU Langone Health, Manhattan, NY 10016, USA.
  • New York University, Manhattan, NY 10003, USA.
  • Inflammatory Bowel Disease Center, NYU Langone Health, New York, NY 10016, USA.
  • NYU Grossman School of Medicine, Manhattan, NY 10016, USA.

ORCID-Profile: Irving Levine, William Schreiber-Stainthorp, Jordan Axelrad

Förderung

  • NIDDK NIH HHS
  • Crohn's and Colitis Foundation
  • Judith Stewart Colton Center
  • NIH
  • NIDDK

Zitieren

APA

Levine, I., Sekhri, S., Schreiber-Stainthorp, W., Locke, B., Delau, O., Elhawary, M., Pandit, K., Meng, X., & Axelrad, J. (2025). GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD. Inflammatory Bowel Diseases, 31(2), 467-475. https://doi.org/10.1093/ibd/izae250

Vancouver

Levine I, Sekhri S, Schreiber-Stainthorp W, Locke B, Delau O, Elhawary M, et al. GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD. Inflammatory Bowel Diseases. 2025;31(2):467-475. doi:10.1093/ibd/izae250

BibTeX
@article{Levine2025,
  author = {Levine, Irving and Sekhri, Shaina and Schreiber-Stainthorp, William and Locke, Brandon and Delau, Olivia and Elhawary, Mohamed and Pandit, Krutika and Meng, Xucong and Axelrad, Jordan},
  title = {GLP-1 Receptor Agonists Confer No Increased Rates of IBD Exacerbation Among Patients With IBD},
  journal = {Inflammatory Bowel Diseases},
  year = {2025},
  volume = {31},
  number = {2},
  pages = {467--475},
  doi = {10.1093/ibd/izae250}
}
Kostenlos starten →